Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 8/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.58 |
| ▸ | SYK | P43405 | 3/20 | 0.56 |
| ▸ | JAK3 | P52333 | 3/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.55 |
| ▸ | STAT6 | P42226 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2479551 | 1.00 | MAPK10 (0.58) | MAPK10MAPK9SYKJAK3IRAK4 | |
| SCHEMBL2480262 | 1.00 | MAPK10 (0.58) | MAPK10MAPK9SYKJAK3IRAK4 | |
| SCHEMBL17452218 | 0.92 | SYK (0.55) | MAPK10MAPK9SYKJAK3IRAK4 | |
| SCHEMBL17452166 | 0.90 | MAPK10 (0.58) | MAPK10MAPK9SYKJAK3IRAK4 | |
| SCHEMBL2693082 | 0.89 | SYK (0.70) | SYKJAK3IRAK4 | |
| SCHEMBL2693079 | 0.89 | SYK (0.70) | SYKJAK3IRAK4 | |
| SCHEMBL2694984 | 0.86 | JAK3 (0.59) | MAPK10MAPK9SYKJAK3IRAK4 | |
| SCHEMBL2694981 | 0.86 | JAK3 (0.59) | MAPK10MAPK9SYKJAK3IRAK4 | |
| SCHEMBL2697795 | 0.84 | MAPK10 (0.67) | MAPK10MAPK9SYKSTAT6MAPK8 | |
| SCHEMBL2474883 | 0.82 | JAK3 (0.72) | MAPK10MAPK9JAK3IRAK4STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | MAPK10 310/4885MAPK9 463/4885SYK 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.